Skip to content

Advertisement

Critical Care

Open Access

Performance of an automated external cardioverter defibrillator for inhospital ventricular malignant arrhythmia

  • S Timerman1,
  • A Bento1,
  • LF Cardoso1,
  • MA Moretti1,
  • NE Sanadi1 and
  • JAF Ramires1
Critical Care20037(Suppl 2):P065

https://doi.org/10.1186/cc1954

Published: 3 March 2003

Keywords

Acute Coronary SyndromeVentricular TachycardiaVentricular ArrhythmiaVentricular FibrillationImplantable Cardioverter Defibrillator

Purpose

Ventricular fibrillation (VF) and ventricular tachycardia (VT) are the major underlying rhythm during inhospital cardiac arrest. For a patient in VF/VT the probability of successful defibrillation and subsequent survival to hospital discharge is directly and negatively related to the time interval between onset of the arrhythmia and delivery of the first shock. The data about this interval in clinical practice is heterogeneous and inconclusive, however the literature estimates it to be about 60 s in monitored units. Continuous ECG monitoring allows identification of such arrhythmias and alert nursing and medical staff. The time delay between the arrhythmic event and human intervention is still a challenge for clinical practice.

Methods

We reported the use of an automated external cardioverter defibrillator (AECD) in 45 patients considered to be at higher risk for malignant arrhythmia for 24–48 hours. The inclusion criteria was acute coronary syndrome, cardiogenic shock and previous episode of sudden death or malignant ventricular arrhythmia. The exclusion criteria was the use of pacemaker or an implantable cardioverter defibrillator and an R-wave amplitude less than 0.7 mV peak to peak at the monitor.

Results

We recorded 17 episodes of VT/VF in three patients. The median time between the beginning of the arrhythmia and the first defibrillation was 33.37 s (range 21–65 s). The sensibility and specificity were 100%. The success of the defibrillation was 94.11% (16/17) for the first shock and 100% (1/1) for the second shock. There was no adverse event during the study period and no episodes of inappropriate therapy delivery (the detection was accurate in all episodes – sensitivity 100%).

Conclusion

AECD was safe and effective. It presents the possibility of providing consistently rapid identification and response to ventricular malignant arrhythmia.

Authors’ Affiliations

(1)
Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brasil

Copyright

© BioMed Central Ltd 2003

Advertisement